Selective Laser Trabeculoplasty (SLT) is a safe, non-invasive glaucoma laser treatment that can help lower eye pressure and reduce or delay the need for daily eye drops in selected patients. Early treatment decisions in glaucoma are about long-term pressure control, preserving vision, and reducing treatment burden—not just avoiding medication.
Standard glaucoma management assumes patients can put eyedrops. Patients with severe rheumatoid arthritis, osteoarthritis, or neurological tremors frequently cannot accurately administer daily eye drops. Recognising these physical limitations is a clinical responsibility. Selective Laser Trabeculoplasty (SLT) serves as an elite, non-invasive primary or adjunctive intervention that lowers intraocular pressure and eliminates the physical burden of drop compliance entirely.
THE ARTHRITIC HAND
Selective Laser Trabeculoplasty (SLT) To Avoid Glaucoma Eye Drops
A 78-year-old grandmother sat in my examination chair, her pressures were not controlled despite using eye drops. She had come for a second opinion. I asked her if she has used her eye drops. She said yes.
I happened to look at her hands, severely twisted by advanced rheumatoid arthritis.
Can you show me how you put eyedrops? She said she wasn’t carrying hers. I handed her a bottle of lubricating eyedrops.
She looked at me with tears in her eyes. Despite her absolute best efforts, her fingers lacked the strength to squeeze the bottle cleanly. Half the medication ran down her cheek every time.
No wonder her intraocular pressures swung unpredictably. Her remaining optic nerve fibres were quietly at risk.
We discussed options then, and she said she wanted to come back in two weeks. I was ready to wait. I performed Selective Laser Trabeculoplasty — a gentle, non-invasive outpatient procedure that takes under ten minutes. The laser targets specific cells in the eye’s drainage network, stimulating the body’s natural cleanup response to improve fluid outflow. Her intraocular pressure dropped into the ideal target zone.
She left the clinic that day free from drop bottles for the first time in years.
True medical accessibility means tailoring the science to fit the physical reality of the person in front of you.
I was one of the first eye doctors in India to offer SLT, fresh after my training at the University of Geneva. Here is an old video of mine from 2011, explaining my treatment philosophy after SLT.
FAQs
Can SLT laser replace glaucoma eye drops?
For some patients, SLT (Selective Laser Trabeculoplasty) can reduce or delay the need for glaucoma eye drops. Others may still need drops later depending on eye pressure, glaucoma type, and long-term response.
Is SLT painful?
SLT is usually well tolerated. The procedure is performed in the clinic, takes only a few minutes, and most people experience little to no discomfort.
How long does SLT last?
The pressure-lowering effect of SLT can last months to years and varies between individuals. In some cases, the laser may be repeated if appropriate.
Does SLT cure glaucoma?
No. SLT does not cure glaucoma or restore vision already lost. Its role is to lower eye pressure and help reduce the risk of future glaucoma progression.
How does SLT laser work to lower eye pressure?
SLT delivers precise, low-energy pulses to the trabecular meshwork — the eye’s internal drainage system. The laser selectively targets pigmented cells, stimulating a natural renewal process that clears microscopic blockages and allows fluid to drain more freely. It does not damage surrounding healthy tissue.
Is SLT a permanent replacement for daily glaucoma drops?
For many patients, SLT successfully controls intraocular pressure for several years, reducing or eliminating the need for daily drops. The effect can diminish over time, but the gentle nature of the procedure allows it to be safely repeated. Your specialist will monitor pressure and advise accordingly.
This page is part of the Advanced Glaucoma Care hub. Read about the full spectrum of glaucoma diagnosis and treatment.
About the Author
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
1500+ Five Star Patient Reviews Google Business Profile
If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation
Read her research on PubMed | Google Scholar | ResearchGate | ORCID
Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735
Leave a review on Google
